Efficacy of neural vision therapy to enhance contrast sensitivity function and visual acuity in low myopia
Accepted 25 November 2007.
Purpose
To evaluate the efficacy and safety of neural vision enhancement technology (NVC, NeuroVision, Inc.) to improve visual acuity and contrast sensitivity function in eyes with low myopia.
Setting
Singapore Eye Research Institute, Singapore, Singapore.
Methods
This noncomparative interventional case series comprised 20 Asian adults between 19 and 53 years of age with low myopia (cycloplegic spherical equivalence [SE] from −0.5 diopter [D] to −1.5 D in the worst eye; astigmatism not exceeding 0.5 D in either eye; uncorrected visual acuity [UCVA] ≤0.7 logMAR) who had NVC treatment. The main outcome measures were distance UCVA, uncorrected contrast sensitivity, refraction, accommodative amplitude, and safety.
Results
All eyes had improvement in UCVA and contrast sensitivity. After treatment, the mean distance UCVA improved by a mean of 2.1 lines on the Early Treatment Diabetic Retinopathy Study logMAR chart. The mean contrast sensitivity improved over a range of spatial frequencies on sine-wave contrast sensitivity chart testing (1.5 to 18 cycles per degree). Follow-up data up to 12 months posttreatment showed that the gains were retained. Treatment did not alter refraction (mean spherical equivalent) or accommodative amplitudes. No adverse effects were reported.
Conclusion
Preliminary evidence suggests NVC treatment is safe and improves UCVA and uncorrected contrast sensitivity in adult patients with low myopia.
From the Singapore Eye Research Institute (Tan, Fong), the Department of Ophthalmology (Tan), Yong Loo Lin School of Medicine, National University of Singapore, and the Singapore National Eye Centre (Tan, Fong), Singapore
Corresponding author: Professor Donald Tan, FRCS, Singapore Eye Research Institute, 11 Third Hospital Avenue, Singapore 168751, Singapore.
Neither author has a financial or proprietary interest in any material or method mentioned.
ABSTRACT